Clinical Trials Browser

Phase 3 × Cognition Disorders × Bevacizumab × Clear all

NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

Phase 3 Completed

Brain Neoplasms, Cognition Disorders, Glioblastoma